The Us Coronary Stent Industry Outlook to 2018 - Bioabsorbable Stents to Drive the Future Growth

The US Coronary Stent Industry Outlook to 2018 - Bioabsorbable Stents to Drive the Future Growth The report titled The US Coronary Stent Industry Outlook to 2018 – Bioabsorbable Stents to Drive the Future Growth provides a comprehensive analysis of the various aspects such as the market size of the US Coronary Stent industry, market segments i.e. drug eluting and bare metal stents and future outlook of the industry. The report also covers the market share of major players in the US. Coronary stent market in the US has witnessed a volatile growth trajectory during the last few years. Recent advancements in coronary stent technology have caused a considerable number of ups and downs in the coronary stent market’s growth trajectory. The arrival of technologically advanced stent designs has led to obsolescence of conventional stents such as bare mental stents. This paradigm shift in patients’ changing preferences of stents has hugely affected the coronary stent market revenues in the country. The coronary stent market in the US has been predominantly occupied by drug eluting stents over the last few years, owing to its relatively higher efficacy and safety. The recent advancements in the field of research and medicine have brought polymer based drug eluting stents in the US market in the recent years. The market for coronary stents is highly concentrated amongst few PCI device manufacturers including Boston Scientific, Abbott Laboratories, Johnson and Johnson and Medtronic. These manufacturers have continued to offer stent equipments that render rapid, accurate, and more effective cardiac recovery possible. Boston Scientific, a leading company PCI devices manufacturing business, accounted for a market share of ~% in 2012, which increased from ~% in 2011. Innovation in drug eluting stent designs, such as improved metal choice, high tensile and coil strength and miniaturization of devices, has promoted the sales of drug eluting stents in the US market...